Lilly Breast Cancer Treatment Lands Another Approval
Lilly completed the CoLucid acquisition in March.
Subscriber Benefit
As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe NowThe U.S. Food and Drug Administration has given another approval for a breast cancer treatment developed by Indianapolis-based Eli Lilly and Co. (NYSE: LLY). The announcement marks the third FDA approval for Verzenio in five months.
The most recent ruling approves Verzenio, also known as abemaciclib, for use in combination with an aromatase inhibitor as an initial endocrine-based therapy for the treatment of postmenopausal women with advanced or metastatic breast cancer. Lilly says the approval follows the results of a successful Phase 3 clinical trial.
"This approval is an important milestone, as it shows that Verzenio plus an aromatase inhibitor substantially reduced tumor size and delayed disease progression in women with HR+, HER2- metastatic breast cancer," said Joyce O’Shaughnessy, chair of the Breast Cancer Research Program at Baylor University Medical Center in Texas. "This information will help inform treatment decisions for each patient, which can be complicated in advanced breast cancer."
In September the FDA also approved Verzenio for use among women with advanced or metastatic breast cancer in combination with an endocrine therapy called fulvestrant, as well as on its own in patients who previously received endocrine therapy and chemotherapy after the cancer had spread.
You can learn more about the approval and the Phase 3 study involved by clicking here.